Esteve to market Eisai's Fycompa in Spain

Japanese drug major Eisai (TYO: 4523) has entered into a new agreement with Spain’s Esteve to co-promote Fycompa (perampanel) in Spain from February 2016. No financial details of the accord were disclosed.

Eisai and Esteve will launch the new indication for the adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in adults and adolescents (≥12 years) with idiopathic generalized epilepsy (IGE) in Spain in early 2016. Perampanel is also indicated in Spain for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

"We are pleased to further strengthen our relationship with Esteve under this new agreement to co-promote perampanel. This collaboration will ensure that we maximize access to our products for people with epilepsy (per indication) in Spain," commented Gary Hendler, president and chief executive of Eisai EMEA.